Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas to Snap Up US Implantable Medical Devices Startup iota
October 16, 2020
- Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
- Remicade Biosimilars Expand Labels into Ankylosing Spondylitis
October 15, 2020
- Takeda Links Arms with Accenture, AWS to Accelerate Digital Transformation
October 15, 2020
- Cefiderocol Demonstrated Non-Inferiority to Meropenem in Global PIII: Shionogi
October 15, 2020
- LEO Pharma, Hokkaido Univ. Pair Up to Identify Therapeutic Targets in Leukoplakia, Alopecia Areata
October 15, 2020
- Kyowa CritiCare Resumes Production of Soft Bag Products
October 14, 2020
- Shionogi Chief Says China JV Marks Pivot from Overly US-Focused Investments
October 14, 2020
- Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
- Padcev Shows Positive PII Results for Urothelial Cancer Patients Ineligible for Cisplatin: Astellas
October 14, 2020
- Ono Licenses Epilepsy Med from South Korean Biopharma
October 14, 2020
- J&J Pauses COVID-19 Vaccine Trials, Japan PI Too
October 14, 2020
- Janssen Japan Chief Chris Hourigan Taking Up New Role for APAC
October 14, 2020
- Big 4 Wholesalers Raided Again over Suspected Bid-Rigging
October 13, 2020
- Nippon Zoki Eyes Alzheimer’s as New R&D Focus, First Up Is Label Expansion for Pain Med
October 13, 2020
- Samsca IV Prodrug Shows Non-Inferiority to Oral Agent
October 13, 2020
- Nichi-Iko, Sanofi in Authorized Generic Pact for ComPlavin
October 13, 2020
- Keytruda Filed for Triple Negative Breast Cancer in Japan: MSD
October 13, 2020
- Kyorin Transfers IP Rights for Novel Immunomodulator to Irish Firm
October 13, 2020
- Despite Price Cuts, Dupixent Netting Bullish Sales to Become Sanofi’s New Flagship
October 12, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…